Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

143.18 +2.47 (+1.76%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup ↗

December 04, 2025

Neurocrine Biosciences (NBIX) combines strong growth, high profitability, and a positive technical breakout setup in the neuroscience sector.

Via Chartmill

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Via The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Soleno just turned profitable for the first time—right as a major fund made its move.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Neurocrine (NBIX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Neurocrine (NBIX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

Via The Motley Fool

Topics Regulatory Compliance

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

Via The Motley Fool

High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration ↗

November 13, 2025

Discover NBIX, a top momentum stock with accelerating EPS growth of 64.5%, rising profit margins, and a perfect technical rating for a potential breakout.

Via Chartmill

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗

November 11, 2025

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.

Via Benzinga

Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 11, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the Affordable Growth Profile ↗

November 05, 2025

Neurocrine Biosciences (NBIX) offers strong growth, solid profitability, and a reasonable valuation, fitting an affordable growth investing strategy.

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗

October 30, 2025

Neurocrine Biosciences (NBIX) is a strong value stock with a debt-free balance sheet, high profitability, and solid growth, trading at a discount to its industry peers.

Via Chartmill

S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? ↗

October 29, 2025

A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100...

Via Benzinga

Topics Economy Stocks

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Q3 2025 Earnings Top Estimates, Driving Stock Momentum ↗

October 28, 2025

Neurocrine Biosciences (NBIX) smashed Q3 2025 earnings estimates, with a 26% EPS beat and strong revenue growth driven by its flagship product INGREZZA®.

Via Chartmill

Neurocrine Bio Surges After Crushing Third-Quarter Expectations ↗

October 28, 2025

Shares of Neurocrine Biosciences raced ahead late Tuesday on better-than-expected third-quarter sales and earnings.

Via Investor's Business Daily

Examining the Future: Neurocrine Biosciences's Earnings Outlook ↗

October 27, 2025

Via Benzinga

What 13 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

October 21, 2025

Via Benzinga

Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews ↗

October 20, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents an Affordable Growth Opportunity ↗

October 15, 2025

Discover Neurocrine Biosciences (NBIX), an affordable growth stock with strong financials, solid profit margins, and a promising pipeline in neuroscience treatments.

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Presents a Compelling Growth and Breakout Opportunity ↗

October 09, 2025

Discover Neurocrine Biosciences (NBIX), a neuroscience leader with strong growth, high profitability, and a positive technical breakout setup.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 25, 2025

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX): An Affordable Growth Candidate in Biotechnology ↗

September 23, 2025

Neurocrine Biosciences (NBIX) offers solid growth and strong profitability at a reasonable valuation. This biotech stock fits the "affordable growth" strategy for long-term investors.

Via Chartmill

Where Neurocrine Biosciences Stands With Analysts ↗

September 22, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX) Screened as a Strong Growth Stock with Bullish Technical Setup ↗

September 17, 2025

Neurocrine Biosciences (NBIX) is a strong growth stock with accelerating revenue, high profitability, and a bullish technical breakout pattern.

Via Chartmill

Breaking Down Neurocrine Biosciences: 12 Analysts Share Their Views ↗

September 05, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Prime GARP Candidate with Strong Growth and Reasonable Valuation ↗

September 02, 2025

Neurocrine Biosciences (NBIX) is a top GARP stock with strong growth, solid profitability, and a reasonable valuation in the biotech sector.

Via Chartmill

Neurocrine (NBIX) Q2 2025 Earnings Call Transcript ↗

August 05, 2025

Via The Motley Fool

Topics Earnings

Neurocrine (NBIX) Q2 Revenue Jumps 17% ↗

August 01, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.